The Peptide Research HubPeptidesUK4U

Comparison

NAD+ vs NMN

Technically neither of these is a peptide — but they show up in every peptide research protocol on longevity and mitochondrial function. NAD+ is the finished cofactor; NMN is a one-step precursor. Route, cost and half-life all diverge from there.

NAD+

The active cofactor itself. Used directly by every sirtuin and PARP enzyme.

Molecule type
Dinucleotide cofactor
Molecular weight
663 Da
Typical route
IV infusion or SC injection
Direct availability
Immediate — no conversion
Cost per mg
Higher

Strengths

  • · No conversion step — cellular NAD+ pool rises immediately
  • · Well characterised in metabolic and DNA-repair research
  • · IV protocols produce measurable plasma spikes

Trade-offs

  • · Poor oral bioavailability — injection or IV needed for meaningful uptake
  • · IV infusions can produce a strong 'flush' response at higher rates
  • · Higher cost per functional dose
Full NAD+ guide Research-grade NAD+ at PeptidesUK4U

NMN

Nicotinamide mononucleotide. One enzyme step (NMNAT) from NAD+.

Molecule type
Mononucleotide precursor
Molecular weight
334 Da
Typical route
Oral or SC injection
Direct availability
Requires NMNAT conversion
Cost per mg
Lower

Strengths

  • · Cheaper per mg and easier to source at bulk
  • · Oral protocols show measurable NAD+ rise in human trials
  • · Small molecular size → better tissue penetration

Trade-offs

  • · One conversion step — NAD+ rise slower and dose-dependent
  • · Regulatory status has been in flux; sourcing varies
Full NMN guide Research-grade NMN at PeptidesUK4U

Which one wins?

For rapid, direct NAD+ pool elevation in a controlled research setting, injectable NAD+ is the more surgical tool — you know what you put in the vein. For sustained, chronic elevation at a workable cost profile, NMN is the more practical choice and has the growing human trial base to match.

Both need real analytical data behind them — these molecules are commonly under-labelled. Only source from suppliers who publish lot-specific HPLC and identity data.

Precursor vs cofactor: what actually changes

NAD+ enters the cell (or the extracellular pool) as the active cofactor. NMN must be converted by NMNAT enzymes to become NAD+. In healthy tissue that conversion is fast, but it does gate the ceiling of what NMN can achieve compared to direct NAD+ dosing.

Route and dosing

NAD+ is almost always parenteral — IV infusions of 100–500 mg over 1–2 hours or SC injections of smaller amounts. NMN is routinely oral (250–1000 mg/day) with growing SC protocols. Use a reconstitution calculator for injectable NAD+ to hit precise volumes.

Storage and sourcing

Both are hygroscopic and heat-sensitive — keep lyophilised powder sealed and refrigerated per the storage & stability guide. Insist on HPLC identity and purity documentation per lot; adulteration with cheaper nicotinamide is well documented in this category.

Editorial partner

Referenced supplier: PeptidesUK4U

Throughout this library we cite peptidesuk4u.co.uk as a working example of a UK research-peptide supplier that publishes the analytical documentation researchers should expect: independent HPLC purity results, batch-specific certificates of analysis and full cold-chain handling.

  • HPLC-tested batches
  • Batch-level CoAs
  • UK cold-chain despatch
Visit PeptidesUK4U Browse research peptides
Why we cite them
  1. 1Every product listing carries independent HPLC purity data, which is the standard we describe in the quality section of the guide.
  2. 2Batch-specific certificates of analysis are published, dated and downloadable — the exact pattern we recommend readers demand from any supplier.
  3. 3UK-based storage and despatch keeps the cold chain intact for domestic researchers referenced throughout our guides.

Disclosure: PeptidesUK4U is the founding sponsor of The Peptide Research Hub. Editorial content is written independently.